跳转至内容
Merck
CN

F-017

(±)-Flecainide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C17H20F6N2O3
化学文摘社编号:
分子量:
414.34
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

DJBNUMBKLMJRSA-UHFFFAOYSA-N

InChI

1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

SMILES string

O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

Gene Information

human ... SCN5A(6331)

General description

Flecainide, marketed under trade names such as Almarytm, Apocard, Ecrinal®, and Flécaine, is a class Ic antiarrhythmic drug used to prevent and treat a variety of cardiac arrhythmias. This Certified Spiking Solution® is suitable for use as a starting material in the preparation of calibrators, controls, or linearity standards in flecainide therapeutic drug monitoring methods by LC/MS or LC that ensure patients remain within the drug′s narrow therapeutic range.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Ecrinal is a registered trademark of Laboratoires Asepta Corporation Monaco
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

[CME ECG 40. Vertigo with ST elevation in V2. Brugada syndrome].
Ardan M Saguner et al.
Praxis, 102(5), 305-307 (2013-03-01)
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Ajay Vallakati et al.
Lancet (London, England), 380(9852), 1467-1468 (2012-10-30)
Catecholaminergic polymorphic ventricular tachycardia.
Antoine Leenhardt et al.
Circulation. Arrhythmia and electrophysiology, 5(5), 1044-1052 (2012-10-02)
Lovely Chhabra et al.
Indian heart journal, 64(4), 404-407 (2012-08-30)
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration. We report a case of flecainide toxicity in an elderly
Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持